araag2/HINT huggingface dataset:
Clinical trial NCT00261495 (phase 3, status: completed)
Conditions: pain
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52
Drugs: oros hydromorphone hcl, oxycodone
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(C)[C@]([H])(C4)[C@]1([H])CCC2=O, CC(=O)OC1=CC=CC=C1C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients with chronic noncancer pain severe enough to require continuous opioid
             therapy (a score of at least 5 in "pain right now" on a 11 point numeric rating scale)
             who have never received an opioid or are currently treated with a weak opioid, and who
             experience insufficient pain control.

        Exclusion Criteria:

          -  Patients who have been treated with strong opioids (including hydromorphone and
             oxycodone) within the last 4 weeks prior to study inclusion or who will probably
             undergo any treatment (e.g. neurological techniques, surgery) within the next 6
             months, which may abruptly alter degree or nature of pain experienced

          -  patients with a history of disease(s), current illness, or therapy which would
             preclude them from participation in the study

          -  and patients who are pregnant or nursing.
Clinical trial NCT01473836 (phase 3, status: completed)
Conditions: intra-abdominal infections
ICD codes: D18.03, C83.73, C84.03, C84.13, C81.73, C81.93, C82.93
Drugs: metronidazole, ceftriaxone sodium
SMILES: [H][C@]1(NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=CC=C2)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCNC1=O)NC(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)CCCCC(C)CC)[C@@H](C)O)[C@@H](C)O, [H][C@]12SCC(CSC3=NC(=O)C(=O)NN3C)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  16 years of age or older.

          -  Diagnosed with intra-abdominal infections or pelvic inflammatory diseases.

          -  Can be obtained a specimen for bacteriological efficacy assessment.

        Exclusion Criteria:

          -  Known or suspected hypersensitivity, intolerance or contraindication to Metronidazole,
             Ceftriaxone sodium, or other cephem antibiotics.

          -  Severe renal dysfunction (creatinine clearance < 30 mL/min.) Reference:
             Cockcroft-Gault calculation formula.

          -  Hepatic dysfunction (AST, ALT, total bilirubin > 3 times upper limit of normal range
             values).

          -  Severe underlying disease; patients in which drug clinical evaluation is difficult
             because of confounding diseases.
Clinical trial NCT00424593 (phase 3, status: completed)
Conditions: back pain without radiation
ICD codes: K62.7, G62.82, N46.024, N46.124, T66.XXXS, Z57.1, N52.35
Drugs: duloxetine, placebo
SMILES: CN(C)CCC[C@]1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male/Female outpatients 18 years of age with chronic low back pain

          -  Females of child bearing potential must test negative on a pregnancy test at visit 1.

        Exclusion Criteria:

          -  Have a serious or unstable diseases of the heart or blood vessels, liver, kidney,
             lungs, or blood-related illness

          -  Problems with decreased blood flow to arms and legs (peripheral vascular disease), or
             other medical conditions

          -  Psychiatric conditions that, in the opinion of the investigator, would affect your
             participation or be likely to lead to hospitalization during the course of the study

          -  Have acute liver injury (such as hepatitis) or severe cirrhosis

          -  Have had previous exposure to duloxetine

          -  Have a body mass index (BMI) over 40

          -  Have a major depressive disorder

          -  Require daily narcotics

          -  Have suicidal risk

          -  Have a presence of any factors/conditions, medical or other, that in the judgment of
             the investigator may interfere with performance of study outcome measures
Clinical trial NCT00642577 (phase 3, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab [avastin], irinotecan, leucovorin, fluorouracil
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  histologically confirmed adenocarcinoma of the colon or rectum, with metastatic
             disease;

          -  >=1 measurable lesion;

          -  ECOG performance status of <=1.

        Exclusion Criteria:

          -  prior systemic therapy for advanced or metastatic disease;

          -  adjuvant or neo-adjuvant treatment for non-metastatic disease in past 6 months;

          -  other malignancy within past 5 years, except cured basal cell cancer of skin or cured
             cancer in situ of cervix;

          -  clinically significant cardiovascular disease in past 6 months.
Clinical trial NCT01467362 (phase 3, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: v0034cr01b, vehicle cream, desonide 0.1% cream
SMILES: CC1=CC(O)=CC(C)=C1Cl, [H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Presenting with atopic dermatitis, dry skin, objective SCORAD < 15,

          -  With xerosis on the body and a xerosis score > = 2 (SCORAD sub-score) on the anterior
             part of lower limbs,

        Exclusion Criteria:

          -  Acute phase of atopic dermatitis

          -  Severe form of atopic dermatitis
Clinical trial NCT00548340 (phase 3, status: completed)
Conditions: primary insomnia
ICD codes: F51.01
Drugs: vec-162 20 mg, placebo, vec-162 50 mg
SMILES: [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]1(CN=C(O)CC)C[C@@]1([H])C1=C2CCOC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females with a diagnosis of primary insomnia as defined in DSM-IV.

          -  Habitual bedtime between 9:00 pm and 1:00 am.

          -  No history or evidence of restless leg syndrome or periodic limb movement disorder or
             sleep apnea.

          -  Patients must sign a written consent form.

        Exclusion Criteria:

          -  History of drug or alcohol abuse as defined in DSM-IV.

          -  History of psychiatric disorders, including Major Depressive Disorder, Generalized
             Anxiety Disorder and delirium.

          -  History of chronic obstructive pulmonary disease (COPD), seizures, sleep apnea,
             narcolepsy, circadian-rhythm sleep disorder, parasomnia or any sleep disorder other
             than chronic insomnia.

          -  Recent history of shift work or jet lag.
Clinical trial NCT00300469 (phase 3, status: completed)
Conditions: mixed dyslipidemia, coronary heart disease, dyslipidemia
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: abt-335, atorvastatin, placebo
SMILES: CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with mixed dyslipidemia

          -  Subjects must agree to utilize adequate birth control methods and to adhere to the
             American Heart Association (AHA) diet

        Exclusion Criteria:

          -  Subjects with unstable medical conditions or medical conditions considered
             inappropriate in a clinical trial.

          -  Patients who are taking certain medications or unstable dose of specific medications.

          -  Women who are pregnant or plan on becoming pregnant, or women who are lactating.
Clinical trial NCT00526474 (phase 3, status: completed)
Conditions: atherosclerosis, ischemia, myocardial infarction, cerebrovascular accident, peripheral arterial disease
ICD codes: I67.2, I70.90, I70.91, I70.0, I70.1, I70.8, I25.83, H35.82, I67.82, I25.6, P91.0, N28.0, P29.4, T79.6XXS, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8, A52.05, I67.81, I67.89, I67.9, I67.841, I67.858, I67.848, A18.2, H11.043, H11.053, H18.463, H35.40, H81.393, I73.9
Drugs: vorapaxar, placebo
SMILES: [H][C@@]12C[C@]3([H])C[C@@H](CC[C@@]3([H])[C@H](\C=C\C3=CC=C(C=N3)C3=CC(F)=CC=C3)[C@]1([H])[C@@H](C)OC2=O)NC(=O)OCC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

        Men and women at least 18 years old with evidence or a history of atherosclerosis involving
        the coronary, cerebral, or peripheral vascular systems by one or more of the following:

          -  history of myocardial infarction (heart attack)

          -  history of ischemic stroke (stroke due to a blocked artery)

          -  history of peripheral arterial disease

        Exclusion Criteria:

          -  history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor,
             or aneurysm

          -  any bleeding disorder or abnormality

          -  sustained severe hypertension or valvular heart disease

          -  current or recent platelet count <100,000 mm^3

          -  planned or ongoing treatment with a blood thinning medication

          -  pregnancy

          -  any significant medical or physiological condition or abnormality that could put the
             subject at increased risk or limit the subject's ability to participate for the
             duration of the study
Clinical trial NCT00322595 (phase 3, status: completed)
Conditions: generalized anxiety disorder
ICD codes: F41.1
Drugs: quetiapine fumarate, paroxetine
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female aged 18 to 65 years;

          -  A diagnosis of generalized anxiety disorder;

          -  Absence of current episode of major depression.

        Exclusion Criteria:

          -  The presence or history of schizophrenia and other psychotic disorders;

          -  Hypertension;

          -  A current diagnosis of cancer, unless in remission for at least 5 years
Clinical trial NCT00331890 (phase 3, status: terminated)
Conditions: acute stroke, cerebral infarction
ICD codes: I63.89, I63.9, I69.320, I69.321, I69.322, I69.390, I69.391
Drugs: citicoline, placebo
SMILES: C[N+](C)(C)CCOP([O-])(=O)OP(O)(=O)OC[C@H]1O[C@H]([C@H](O)[C@@H]1O)N1C=CC(N)=NC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    with 2078 patients, a statistical stopping boundary has now been crossed
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, >18 years old

          -  Patients must be treated within 24 hours of their initial stroke symptoms onset.

          -  Patients with a measurable focal neurological deficit lasting for a minimum of 60
             minutes.

          -  Patients must have a CT scan and/or conventional MRI compatible with the clinical
             diagnosis of acute ischemic stroke prior to being randomized.

          -  Patients must have an acute ischemic stroke referable to the middle cerebral artery
             territory

          -  At inclusion, NIHSS score > 7, with at least 2 of these points from sections 5 & 6
             (motor)

          -  Immediately (i.e. minutes) pre-stroke, MRS < 2

          -  Women of childbearing potential must have a negative pregnancy test prior to enrolment

          -  Signed informed consent

        Exclusion Criteria:

          -  Patients in coma: patients having a score of 2 or higher in the items regarding the
             level of consciousness in the NIHSS (1a)

          -  CT or conventional MRI evidence of brain tumor, cerebral edema with a clinically
             significant mass midline shift with compression of the ventricles, brainstem or
             cerebellar infarction, subarachnoid and/or intracerebral and/or intraventricular
             hemorrhage

          -  History of ventricular dysrhythmias, acute myocardial infarction within 72 hours prior
             to enrolment, unstable angina, decompensated congestive heart failure or any other
             acute, severe, uncontrollable or sustained cardiovascular condition that, in the
             Investigator's opinion, may interfere with effective participation in the study

          -  Previous disorders that may confound the interpretation of the neurological scales

          -  Drug addiction-related disorders

          -  Pre existing dementia, when dementia implies a disability, measured as an score of 2
             or higher in the previous MRS

          -  Pre existing medical condition that, in the Investigator's opinion, may interfere with
             the patient's suitability and participation in the study

          -  Patients participating in another clinical trial or receiving a non-approved drug
             (clinical investigational drug) less than 30 days prior to screening

          -  Patients under current treatment with citicoline
Clinical trial NCT01355276 (phase 3, status: completed)
Conditions: dyspepsia
ICD codes: K30
Drugs: cinitapride, domperidone
SMILES: CCOC1=CC(N)=C(C=C1C(=O)NC1CCN(CC2CCC=CC2)CC1)[N+]([O-])=O, ClC1=CC2=C(C=C1)N(C1CCN(CCCN3C(=O)NC4=CC=CC=C34)CC1)C(=O)N2
Eligibility criteria:

        Inclusion:

          1. Aged between 18~65 years, both males and females;

          2. Patients with symptoms of mild to moderate functional dyspepsia;

          3. Symptoms related to dyspepsia were developed 6 months ago and early satiety or/and
             discomfort after meal were developed in the past 3 months;

          4. Gastrointestinal malignancy, peptic ulcer, liver, gallbladder and pancreas diseases
             were excluded through gastroscopy, B-ultrasonography and laboratory examination within
             4 weeks prior to administration (endoscopy results considered to be clinically
             unrelated will not be excluded, such as small hiatal hernia and chronic nonatrophic
             pangastritis);

          5. Patient has signed informed consent form.

        Exclusion criteria

          1. Patients with gastroesophageal reflux and/or irritable bowel syndrome;

          2. Acid regurgitation more than once per week;

          3. Previously received abdominal surgery (except appendectomy and herniorrhaphy);

          4. A history of gastric or duodenal ulcer;

          5. Patients with depression and anxiety neurosis;

          6. Patients with arrhythmia;

          7. QTc more than 0.5s;

          8. Hepatic and renal insufficiency: AST or/and ALT equal to or above 1.5 times of the
             upper normal limit; Cr above the upper normal limit;

          9. Pathological lactorrhea;

         10. Patients with alcohol abuse (daily alcohol intake more than 40g), drug dependence or
             neuropsychiatric disorders that are difficult to control, as well as others who are
             not appropriate to participate in a drug trial;

         11. Pregnant or lactating women;

         12. Patients who require other therapy to change gastrointestinal mobility;

         13. Patients who are participating or participated in other drug clinical trial within 3
             months prior to entry;

         14. Known to be allergic to cinitapride; Patients who are considered by investigators to
             be inappropriate to participate.
Clinical trial NCT00239681 (phase 3, status: terminated)
Conditions: elevated high-sensitivity c-reactive protein (hscrp)
ICD codes: R79.82
Drugs: rosuvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O
Reason stopped: 
    see detailed description for reason.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men 50 years or older, women 60 years or older

          -  Low to normal levels of low density lipoprotein (LDL) cholesterol (< 130mg/dL)

          -  Elevated levels of C-Reactive Protein (CRP) > 2.0 mg/L

        Exclusion Criteria:

          -  History of cardiovascular or cerebrovascular events

          -  Active liver disease

          -  Diabetes mellitus

          -  Uncontrolled hypertension or hypothyroidism

          -  History of certain malignancies

          -  Chronic inflammatory conditions

          -  History of alcohol or drug abuse
Clinical trial NCT00438360 (phase 3, status: completed)
Conditions: chronic plaque psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: cyclosporine a microemulsion, placebo
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Outpatients 18 years of age and older (max 65 years)

          -  Patients with chronic plaque psoriasis on disease remission (i.e. PASI ≤75% of PASI
             before cyclosporine continuous treatment course) entering a maintenance period

          -  Disease remission obtained with only cyclosporine as systemic therapy (maximum dose 5
             mg/kg/day) for >8 weeks and <16 weeks

          -  PASI still <75% of PASI before cyclosporine continuous treatment course, at
             randomization to study treatment (8±2 days after disease remission)

        Exclusion criteria:

          -  Abnormal renal function (creatinine ≥ 10% the upper limit of the reference range)

          -  Severe chronic degenerative diseases

          -  Severe uncontrolled hypertension

          -  Body weigh >110 kg

          -  Abnormal liver function

          -  Hyperkalemia or hyperuricemia

          -  Clinically significant impairment of hematopoietic and cardiovascular function

          -  Concomitant therapy with nephrotoxic medications

          -  Patients with malignancy or a history of malignancy

          -  Females of childbearing potential who are planning to become pregnant, who are
             pregnant and/or lactating, who are unwilling to use effective means of contraception

          -  Clinically significant uncontrolled bacterial, viral or fungal infection

          -  Evidence of drug and/or alcohol abuse
Clinical trial NCT01007851 (phase 3, status: terminated)
Conditions: infertility
ICD codes: N46.8, N46.9, N97.9, N97.0, N97.1, N97.2, N97.8
Drugs: triptorelin acetate, nacl %0.9
SMILES: CC(C)C[C@H](NC(=O)[C@@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1CCC[C@H]1C(=O)NCC(N)=O, [Na+].[Cl-]
Reason stopped: 
    lower than anticipated recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Women undergoing embryo transfer following controlled ovarian hyperstimulation with a
             fixed GnRH antagonist protocol, oocyte pick-up and ICSI.

          -  Embryo transfer performed on day 3

        Exclusion Criteria:

          -  Participation in another trial that was being conducted in our unit at the same time.

          -  Preimplantation genetic screening cycles.

          -  Day 5 embryo transfers.
Clinical trial NCT01143272 (phase 3, status: terminated)
Conditions: antibiotic-associated diarrhea, clostridium difficile, diarrhea
ICD codes: K59.1, R19.7, P78.3, K58.0, K58.9, A04.71, A04.72, K59.1, R19.7, P78.3, K58.0, K58.9
Drugs: saccharomyces boulardii, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    masked independent interim analysis: completion of the trial was unlikely.
  
Eligibility criteria:

        Inclusion Criteria:

          -  adult patient (≥ 18 years)

          -  patient hospitalized

          -  patient receives systemic antibiotic treatment

          -  patient contractually capable

          -  patient able to follow study procedures

          -  informed consent of patient

        Exclusion Criteria:

          -  allergy against yeast and/or Perenterol® forte und/oder placebos containing
             Saccharomyces cerevisiae HANSEN CBS 5926, lactose-monohydrate, magnesium stearate,
             gelatine, sodium dodecyl sulfate, titan dioxide, microcrystalline cellulose.

          -  central venous catheter

          -  immunosuppression

          -  diarrhoea and/or chronic diarrhoea

          -  regular intake of Perenterol®, Perenterol® forte oder Yomogi® in the last seven days
             before the start of the study

          -  systemic antimycotic treatment

          -  systemic antibiotic treatment within the last 6 weeks

          -  no protection against conception, pregnancy, or lactation

          -  simultaneous participation in other clinical trials
Clinical trial NCT00736879 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: dapagliflozin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and females, ≥18 to ≤77 years old, with type 2 diabetes mellitus

          -  Subjects must have central laboratory pre-randomization A1C ≥7.0 and ≤ 10.0%

          -  C-peptide ≥ 1.0 ng/mL (0.34 nmol/L)

          -  Body Mass Index ≤ 45 kg/m²

          -  Must be able to perform self monitoring of blood glucose

        Exclusion Criteria:

          -  aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3* upper limit
             of normal (ULN)

          -  Serum Total bilirubin >2 mg/dL (34.2 µmol/L)

          -  Creatinine kinase >3* ULN

          -  Serum creatinine ≥1.50 mg/dL (133 µmol/L) for male subjects, ≥1.40 mg/dL (124 µmol/L)
             for female subjects

          -  Currently unstable or serious cardiovascular, renal, hepatic, hematological,
             oncological, endocrine, psychiatric, or rheumatic diseases